activE clinical trials

Recruiting Participants as of February 2017


Terminated (unable to recruit patients and/or IRB issues)

Unknown Status

publishEd research

Human Studies

Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice (2016)

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis (2016)

Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study (2016)

Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis (2016)

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years (2016)

THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms (2016)

THC:CBD in Daily Practice: Available Data from UK, Germany and Spain (2016)

Multiple sclerosis, cannabis, and cognition: A structural MRI study (2015)

Utilization and patients’ perceptions of the effectiveness of pain treatments in multiple sclerosis: A cross-sectional survey (2015)

Effects of cannabis on cognition in patients with MS: a psychometric and MRI study (2014)

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis (2014)

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters (2014)

The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS (2014)

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis (2013)

A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine (2013)

Multiple sclerosis and extract of cannabis: results of the MUSEC trial (2012)

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial (2012)

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine (2011)

Effects of cannabis on cognitive function in patients with multiple sclerosis (2011)

Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility (2011)

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis (2010)

Standardized cannabis in multiple sclerosis: a case report (2010)

Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study (2009)

Willingness to pay for a treatment for pain in multiple sclerosis (2009)

Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients’ expectations? (2008)

Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol (2008)

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis (2007)

Cannabis; adverse effects from an oromucosal spray (2007)

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain (2007)

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial (2007)

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis (2006)

Cannabis use in patients with multiple sclerosis (2006)

Medicinal marijuana use: experiences of people with multiple sclerosis (2006)

The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS) (2006)

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up (2005)

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis (2005)

Cannabinoid influence on cytokine profile in multiple sclerosis (2005)

The medicinal use of cannabis in the UK: results of a nationwide survey (2005)

Patterns of cannabis use among patients with multiple sclerosis (2004)

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients (2004)

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis (2004)

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study (2004)

What affects your MS? Responses to an anonymous, Internet-based epidemiological survey (2004)

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies (2004)

The effect of cannabis on tremor in patients with multiple sclerosis (2004)

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms (2003)

Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis (2003)

Safety, tolerability, and efficacy of orally administered cannabinoids in MS (2002)

Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis (2000)

The perceived effects of smoked cannabis on patients with multiple sclerosis (1997)

Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers (1994)

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis (1989)

Delta-9-THC in the treatment of spasticity associated with multiple sclerosis (1987)

Treatment of human spasticity with delta 9-tetrahydrocannabinol (1981)

Marijuana may lessen spasticity of MS (1979)

Rodent Studies

Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis (2017)

Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis (2016)

Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids (2015)

Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors (2013)

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors (2013)

Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis (2011)

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice (2011)

Multiple sclerosis and cannabis: a cognitive and psychiatric study (2008)

Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis (2008)

Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors (2007)

New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application (2004)

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis (2003)

Cannabinoids control spasticity and tremor in a multiple sclerosis model (2000)

Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis (1989)

In Vitro Studies

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress (2012)


Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis (2017)

Use of Cannabinoids for Spasticity and Pain Management in MS (2016)

Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines (2016)

Recent updates in imperative natural compounds for healthy brain and nerve function: A systematic review of implications for multiple sclerosis (2016)

Pros and cons of medical cannabis use by people with chronic brain disorders (2016)

Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (2016)

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis (2016)

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review (2015)

Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis (2015)

Clinical perspectives on medical marijuana (cannabis) for neurologic disorders (2015)

What to make of cannabis and cognition in MS: In search of clarity amidst the haze (2015)

Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders (2015)

The therapeutic potential of cannabinoids for movement disorders (2015)

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology (2014)

Complementary and alternative medical therapies in multiple sclerosis–the American Academy of Neurology guidelines: a commentary (2014)

Medical marijuana in neurology (2014)

Current and future drugs for treatment of MS-associated bladder dysfunction (2014)

Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis (2014)

Advances in the management of multiple sclerosis spasticity: recent clinical trials (2014)

Advances in the management of MS spasticity: recent observational studies (2014)

Cannabidiol: promise and pitfalls (2014)

Cannabinoids: new promising agents in the treatment of neurological diseases (2014)

The endocannabinoid system: a putative role in neurodegenerative diseases (2013)

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (2012)

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis (2012)

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach (2012)

The therapeutic potential of cannabis and cannabinoids (2012)

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity (2012)

Potential control of multiple sclerosis by cannabis and the endocannabinoid system (2012)

Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? (2012)

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (2012)

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis (2012)

Cannabinoid modulation of neuroinflammatory disorders (2012)

Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis (2012)

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (2011)

Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data (2011)

Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction (2011)

Cannabinoids: potential targets for bladder dysfunction (2011)

Role of cannabinoids in multiple sclerosis (2011)

Cannabis-based medicines in multiple sclerosis–a review of clinical studies (2010)

Functional role of cannabinoid receptors in urinary bladder (2010)

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids (2010)

Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression (2010)

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review (2009)

Do cannabinoids reduce multiple sclerosis-related spasticity? (2009)

Cannabinoids, multiple sclerosis and neuroprotection (2009)

Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis (2009)

Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration (2009)

Cannabidiol: a promising drug for neurodegenerative disorders? (2009)

A review of complementary and alternative medicine (CAM) by people with multiple sclerosis (2009)

The endocannabinoid system and multiple sclerosis (2008)

Multiple sclerosis, cannabinoids, and cognition (2008)

Cannabinoid control of neuroinflammation related to multiple sclerosis (2007)

Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances (2007)

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine (2007)

Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain (2006)

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol (2006)

Sativex for the management of multiple sclerosis symptoms (2005)

From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases (2005)

The safety of cannabinoids for the treatment of multiple sclerosis (2005)

Towards cannabis and cannabinoid treatment of multiple sclerosis (2004)

Medicinal cannabis extracts for the treatment of multiple sclerosis (2004)

Cannabis oils made with hemp seed or evening primrose oil may be especially beneficial for ms: 

Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by Hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients (2015)

Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention (2014)

Immunomodulatory and therapeutic effects of Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients (2013)

Association of Expanded Disability Status Scale and Cytokines after Intervention with Co-supplemented Hemp Seed, Evening Primrose Oils and Hot-natured Diet in Multiple Sclerosis Patients (2013)

Diet changes:

“Disease modifying nutricals” for multiple sclerosis (2015)